| | You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online | | |
| | Even if you have voted by proxy, you may still vote online | | |
| | | Page | | ||||
| | | | 2 | | | ||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | 25 | | | ||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | |
Name | | | Age | | | Principal Occupation/ Position | |
Class at the | |||||||
| |||||||
Fred E. Cohen, M.D., D.Phil. | | | | | Director | | |
Norman Payson, M.D. | | | | | Director | | |
Beth Seidenberg, M.D. | | | | | | ||
Class I directors continuing in office until the 2023 Annual Meeting of Stockholders | | ||||||
Malissia Clinton* | | | 53 | | | Director | |
Kevin Gordon | | | 59 | | | Director | |
Cheryl Scott | | | 72 | | | Director | |
Class II directors continuing in office ntil the | | ||||||
Peter Anevski | | | 54 | | | Chief Executive Officer and Director | |
Roger Holstein | | | 70 | | | Director | |
Jeff Park | | | 50 | | | Director | |
David Schlanger | | | 62 | | | Executive Chairman | |
Name | | | Audit | | | Compensation | | | Nominating and Corporate Governance | | |||||||||
Malissia Clinton** | | | | | | | | | | | | | | | | | X | | |
Fred Cohen, M.D., D.Phil. | | | | | | | | | | | X* | | | | | | | | |
Kevin Gordon | | | | | X | | | | | | | | | | | | X | | |
Roger Holstein | | | | | | | | | | | X | | | | | | | | |
Jeff Park | | | | | X* | | | | | | X | | | | | | | | |
Norman Payson, M.D. | | | | | X | | | | | | | | | | | | X* | | |
Cheryl Scott | | | | | | | | | | | | | | | | | X | | |
Beth Seidenberg, M.D. | | | | | | | | | | | X | | | | | | | | |
| | Board Diversity Matrix (As of April 14, 2022) | | | ||||||||||||||||
| | Total Number of Directors | | | | 10 | | | ||||||||||||
| | | | | | Female | | | | Male | | | | Non-Binary | | | | Did Not Disclose Gender | | |
| | Part I: Gender Identity | | | ||||||||||||||||
| | Directors | | | | 3 | | | | 7 | | | | — | | | | 0 | | |
| | Part II: Demographic Background | | | ||||||||||||||||
| | African American or Black | | | | 1 | | | | — | | | | — | | | | — | | |
| | Alaskan Native or Native American | | | | — | | | | — | | | | — | | | | — | | |
| | Asian | | | | — | | | | — | | | | — | | | | — | | |
| | Hispanic or Latinx | | | | — | | | | — | | | | — | | | | — | | |
| | Native Hawaiian or Pacific Islander | | | | — | | | | — | | | | — | | | | — | | |
| | White | | | | 2 | | | | 7 | | | | — | | | | — | | |
| | Two or More Races or Ethnicities | | | | — | | | | — | | | | — | | | | — | | |
| | LGBTQ+ | | | | 1 | | | ||||||||||||
| | Did Not Disclose Demographic Background | | | | 0 | | |
| | Fiscal Year Ended | | | Fiscal Year Ended | | ||||||||||||||
| | 2019 | | 2018 | | | 2021 | | 2020 | | ||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||
Audit Fees(1) | | | $ | 782 | | | | $ | 142 | | | | $700 | | $775 | | ||||
Audit-related Fees(2) | | | | 250 | | | | | — | | | | — | | — | | ||||
Tax Fees(3) | | | | 49 | | | | | — | | | | 119 | | 112 | | ||||
All Other Fees | | | | — | | | | | — | | | | | — | | 4 | | |||
Total Fees | | | $ | 1,081 | | | | $ | 142 | | | | $819 | | $891 | |
Name | | | Age | | | Principal Position | | |||
David Schlanger | | | | 62 | | | | Executive Chairman | | |
Peter Anevski | | | | | 54 | | | | Chief Executive Officer and Director | |
Jennifer Bealer | | | | 41 | | | | Executive Vice President, General Counsel and Secretary | | |
Mark Livingston | | | | | 56 | | | | Chief Financial Officer | |
Michael Sturmer | | | | | 45 | | | | President | |
| What We Do | | | What We Don’t Do | |
| ✓ Deliver a significant portion of executive compensation through long-term equity to align interests with stockholders | | | X No pledging or hedging of Progyny stock | |
| ✓ Engage an independent compensation consultant | | | X No excessive perquisites | |
| ✓ Benchmark certain pay against industry peers to offer market-competitive compensation | | | X No supplemental executive retirement plans | |
| ✓ Set challenging company metrics and targets | | | X No compensation-related tax gross-ups | |
| ✓ Conduct an annual executive compensation review | | | X No incentives that encourage excessive risk- taking | |
| Apollo Medical Holding Inc. | | | Healthstream Inc. | |
| Benefitfocus, Inc. | | | HMS Holdings Corp | |
| Care.com, Inc. | | | National Research Corp | |
| Castlight Health Inc. | | | NextGen Healthcare Inc. | |
| Corvel Corp | | | Tabula Rasa Healthcare Inc. | |
| Digirad Corp | | | Teladoc Health Inc. | |
| Evolent Health Inc. | | | Tivity Health Inc. | |
| HeathEquity Inc. | | | Wageworks, Inc. | |
Named Executive Officer | | | Fiscal 2021 Base Salary | | |||
David Schlanger | | | | $ | 500,000 | | |
Peter Anevski | | | | $ | 425,000 | | |
Mark Livingston | | | | $ | 425,000 | | |
Jennifer Bealer | | | | $ | 300,000 | | |
Lisa Greenbaum | | | | $ | 113,751(1) | | |
Named Executive Officer | | | Target Percentage Salary | | |||
David Schlanger | | | | | 75% | | |
Peter Anevski | | | | | 75% | | |
Mark Livingston | | | | | 60% | | |
Jennifer Bealer | | | | | 40% | | |
Lisa Greenbaum(1) | | | | | N/A | | |
| Performance Metric/Goal | | | Actual | | | Assessment | |
| Sales and Account Management – grow client base, upsells to existing clients and client retention | | | Despite disruption due to COVID-19, entered 2022 with a large contractual backlog of estimated annual revenues | | | Exceeds expectations | |
| Clinical Outcomes and Scientific Leadership – generate industry leading clinical outcomes that exceed national averages | | | All clinical outcomes substantially exceeded most recently reported national averages and are industry leading | | | Exceeds expectations | |
| Member Services – continue to improve and refine the member experience to maintain competitive differentiation | | | NPS score of 81+ by year-end and average member satisfaction survey score of 4.9 out of 5 | | | Exceeds expectations | |
| Provider Network and Relations – continue to have a high quality network and maintain unique collaborative relationship with network providers | | | Continued to grow network and created clinic watch lists to ensure alignment with high standards | | | Meets expectations | |
| Performance Metric/Goal | | | Actual | | | Assessment | |
| Organization – maintain the unique mission-driven and collaborative culture | | | Positive results from employee engagement survey and low attrition | | | Exceeds expectations | |
| Strategic – determine priority areas for growth | | | Determined priority areas for board’s consideration, including male infertility services, PGNY among fastest ever from IPO to S&P400 | | | Exceeds expectations | |
Name | | | Target | | | Overall Assessment | | | Actual Bonus Payout | | ||||||
David Schlanger | | | | $ | 375,000 | | | | Meets expectations | | | | $ | 350,000 | | |
Peter Anevski | | | | $ | 318,750 | | | | Exceeds expectations | | | | $ | 350,000 | | |
Mark Livingston | | | | $ | 255,000 | | | | Meets expectations | | | | $ | 255,000 | | |
Jennifer Bealer | | | | $ | 120,000 | | | | Exceeds expectations | | | | $ | 150,000 | | |
Lisa Greenbaum | | | N/A | | | N/A | | | N/A | |
Named Executive Officer | | | 2021 Stock Options Granted | | | 2021 RSUs Granted | | ||||||
Mark Livingston | | | | | 270,000 | | | | | | 82,000 | | |
Jennifer Bealer | | | | | 135,000 | | | | | | 37,000 | | |
Lisa Greenbaum | | | | | 20,000 | | | | | | 7,000 | | |
Name and Principal Position during 2021 | | | Year | | | Salary ($) | | | Bonus ($)(1) | | | Stock Awards ($)(2) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($)(3) | | | All Other Compensation ($)(4) | | | Total ($) | | ||||||||||||||||||||||||
David Schlanger Chief Executive Officer | | | | | 2021 | | | | | | 500,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,462 | | | | | | 862,462 | | |
| | | | | 2020 | | | | | | 500,000 | | | | | | 125,000 | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,312 | | | | | | 987,312 | | |
| | | | | 2019 | | | | | | 431,250 | | | | | | — | | | | | | — | | | | | | 4,240,075 | | | | | | 250,000 | | | | | | 42,871 | | | | | | 4,964,196 | | |
Peter Anevski President and Chief Operating Officer | | | | | 2021 | | | | | | 425,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 10,770 | | | | | | 785,770 | | |
| | | | | 2020 | | | | | | 425,000 | | | | | | 156,250 | | | | | | — | | | | | | — | | | | | | 318,750 | | | | | | 9,861 | | | | | | 909,861 | | |
| | | | | 2019 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | 3,865,951 | | | | | | 250,000 | | | | | | 30,714 | | | | | | 4,251,665 | | |
Mark Livingston Chief Financial Officer | | | | | 2021 | | | | | | 425,000 | | | | | | — | | | | | | 4,521,210 | | | | | | 7,586,995 | | | | | | 255,000 | | | | | | 275,467 | | | | | | 13,063,672 | | |
| | | | | 2020 | | | | | | 389,776 | | | | | | 127,812 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 207,188 | | | | | | 132,230 | | | | | | 1,251,295 | | |
Jennifer Bealer Executive Vice President and General Counsel | | | | | 2021 | | | | | | 300,000 | | | | | | — | | | | | | 2,299,260 | | | | | | 4,309,487 | | | | | | 150,000 | | | | | | 10,170 | | | | | | 7,068,917 | | |
| | | | | 2020 | | | | | | 300,000 | | | | | | 70,000 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 120,000 | | | | | | 9,120 | | | | | | 893,409 | | |
Lisa Greenbaum(5) Executive Vice President and Chief Client Officer | | | | | 2021 | | | | | | 113,751 | | | | | | — | | | | | | 299,460 | | | | | | 438,920 | | | | | | — | | | | | | 26,054 | | | | | | 878,185 | | |
| | | | | 2020 | | | | | | 325,000 | | | | | | 75,000 | | | | | | 81,060 | | | | | | 94,529 | | | | | | 225,000 | | | | | | 56,574 | | | | | | 857,163 | | |
Name and Principal Position | | | Year | | | Salary | | | Option Awards(1) | | | Non-Equity Incentive Plan Compensation(2) | | | All Other Compensation(3) | | | Total | | ||||||||||||||||||
David Schlanger Chief Executive Officer | | | | | 2019 | | | | | $ | 431,250 | | | | | $ | 4,240,075 | | | | | $ | 250,000 | | | | | $ | 42,871 | | | | | $ | 4,964,196 | | |
| | | 2018 | | | | | | 350,000 | | | | | | 244,812 | | | | | | 175,000 | | | | | | 74,574 | | | | | | 844,386 | | | ||
Peter Anevski President, Chief Financial & Operating Officer | | | | | 2019 | | | | | | 375,000 | | | | | | 3,865,951 | | | | | | 250,000 | | | | | | 30,714 | | | | | | 4,521,665 | | |
| | | 2018 | | | | | | 325,000 | | | | | | 139,893 | | | | | | 163,000 | | | | | | 53,698 | | | | | | 681,591 | | | ||
Karin Ajmani(4) Former Executive Vice President, Chief of Strategic Development | | | | | 2019 | | | | | | 325,031 | | | | | | 374,122 | | | | | | — | | | | | | 10,346 | | | | | | 709,499 | | |
| | | 2018 | | | | | | 325,000 | | | | | | — | | | | | | 100,000 | | | | | | 9,520 | | | | | | 434,520 | | |
Name | | | Grant Date | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise or Base Price of Option Awards ($/Sh) | | | Grant Date Fair Value of Stock and Option Awards($)(1) | | ||||||||||||||||||||||||
David Schlanger | | | | | N/A | | | | | | — | | | | | | 375,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Peter Anevski | | | | | N/A | | | | | | — | | | | | | 318,750(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | N/A | | | | | | — | | | | | | 255,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 42.78 | | | | | | 438,920 | | | ||
| | | 09/01/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000 | | | | | | — | | | | | | — | | | | | | 4,221,750 | | | ||
| | | 09/01/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 250,000 | | | | | | 56.29 | | | | | | 7,148,075 | | | ||
Jennifer Bealer | | | | | N/A | | | | | | — | | | | | | 120,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,000 | | | | | | 42.78 | | | | | | 438,920 | | | ||
| | | 11/08/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | 30,000 | | | | | | — | | | | | | — | | | | | | 1,999,800 | | | ||
| | | 11/08/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 115,000 | | | | | | 66.66 | | | | | | 3,870,567 | | | ||
Lisa Greenbaum | | | | | N/A | | | | | | — | | | | | | 325,000(2) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000 | | | | | | — | | | | | | — | | | | | | 299,460 | | | ||
| | | 03/03/21(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 42.78 | | | | | | 438,920 | | |
| | | Option Awards(1) | | ||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options Exercisable | | | Number of Securities Underlying Unexercised Options Unexercisable | | | Option Exercise Price | | | Option Expiration Date | | |||||||||
David Schlanger | | | | | 2,596,316 | | | | | | 1,618,068(2) | | | | | $ | 0.91 | | | | 8/3/2027 | |
| | | 147,871 | | | | | | 54,923(2) | | | | | $ | 1.50 | | | | 8/16/2028 | | ||
| | | — | | | | | | 1,870,022(3) | | | | | $ | 3.96 | | | | 5/23/2029 | | ||
Peter Anevski | | | | | 142,619 | | | | | | 924,610(2) | | | | | $ | 0.91 | | | | 8/3/2027 | |
| | | 5,071 | | | | | | 31,385(2) | | | | | $ | 1.50 | | | | 8/16/2028 | | ||
| | | — | | | | | | 1,705,020(3) | | | | | $ | 3.96 | | | | 5/23/2029 | | ||
Karin Ajmani | | | | | 622,386 | | | | | | — | | | | | $ | 0.87 | | | | 6/2/2020 (5) | |
| | | 43,047 | | | | | | 344,375(4) | | | | | $ | 0.91 | | | | 6/2/2020 (5) | | ||
| | | — | | | | | | 165,001(3) | | | | | $ | 3.96 | | | | 6/2/2020 (5) | |
| | | | | | | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Options (#)Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(1) | | |||||||||||||||||||||
David Schlanger | | | | | 5/24/2019 | | | | | | 1,207,723(2) | | | | | | 662,299(2) | | | | | | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | | | 8/17/2018 | | | | | | 202,794(3) | | | | | | — | | | | | | 1.5000 | | | | | | 8/16/2028 | | | | | | — | | | | | | — | | |
| | | | | 8/4/2017 | | | | | | 2,234,385(3) | | | | | | — | | | | | | 0.9091 | | | | | | 8/3/2027 | | | | | | — | | | | | | — | | |
Peter Anevski | | | | | 5/24/2019 | | | | | | 1,017,774(2) | | | | | | 603,862(2) | | | | | | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | | | 8/17/2018 | | | | | | 34,042(3) | | | | | | — | | | | | | 1.5000 | | | | | | 8/16/2028 | | | | | | — | | | | | | — | | |
| | | | | 8/4/2017 | | | | | | 472,107(3) | | | | | | — | | | | | | 0.9091 | | | | | | 8/3/2027 | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | 9/01/2021 | | | | | | — | | | | | | 250,000(4) | | | | | | 56.2900 | | | | | | 08/31/2031 | | | | | | — | | | | | | — | | |
| | | | | 9/01/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000(4) | | | | | | 3,776,250 | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | 20,000(5) | | | | | | 42.7800 | | | | | | 03/02/2031 | | | | | | — | | | | | | — | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000(5) | | | | | | 352,450 | | |
| | | | | 5/4/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000(6) | | | | | | 251,750 | | |
| | | | | 3/9/2020 | | | | | | 1,126(7) | | | | | | 5,060(7) | | | | | | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | |
| | | | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,967(7) | | | | | | 99,038 | | |
| | | | | 6/4/2019 | | | | | | 13,750(8) | | | | | | 116,877(8) | | | | | | 3.9545 | | | | | | 6/3/2029 | | | | | | — | | | | | | — | | |
Jennifer Bealer | | | | | 11/08/2021 | | | | | | — | | | | | | 115,000(9) | | | | | | 66.6600 | | | | | | 11/07/2031 | | | | | | — | | | | | | — | | |
| | | | | 11/08/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 30,000(9) | | | | | | 1,510,500 | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | 20,000(5) | | | | | | 42.7800 | | | | | | 03/02/2031 | | | | | | — | | | | | | — | | |
| | | | | 3/03/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,000(5) | | | | | | 352,450 | | |
| | | | | 5/4/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,000(6) | | | | | | 251,750 | | |
| | | | | 3/9/2020 | | | | | | 563(7) | | | | | | 5,060(7) | | | | | | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | |
| | | | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,967(7) | | | | | | 99,038 | | |
| | | | | 5/24/2019 | | | | | | 6,875(2) | | | | | | 54,438(2) | | | | | | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | | | 5/22/2019 | | | | | | 1,265(2) | | | | | | 9,488(2) | | | | | | 3.9545 | | | | | | 5/21/2029 | | | | | | — | | | | | | — | | |
Lisa Greenbaum(10) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||
Name | | | Number of Shares Acquired on Exercise (#)(1) | | | Value Realized on Exercise ($)(7) | | | Number of Shares Acquired on Vesting (#)(1) | | | Value Realized on Vesting ($)(8) | | ||||||||||||
David Schlanger | | | | | 1,500,000 | | | | | | 79,489,166 | | | | | | — | | | | | | — | | |
Peter Anevski | | | | | 403,538 | | | | | | 23,140,575 | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | 78,439(2) | | | | | | 4,689,959 | | | | | | 4,033(3) | | | | | | 212,696 | | |
Jennifer Bealer | | | | | 71,579(4) | | | | | | 3,658,585 | | | | | | 4,033 | | | | | | 212,696 | | |
Lisa Greenbaum | | | | | 57,668(5) | | | | | | 2,829,553 | | | | | | 876(6) | | | | | | 36,941 | | |
Name | | | Benefit | | | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | | | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($)(7) | | ||||||
David Schlanger | | | Cash | | | | | 850,000(1) | | | | | | 850,000(1) | | |
| | | Equity Acceleration | | | | | 21,690,175(3) | | | | | | 30,727,693(4) | | |
| | | All Other Payments or Benefits | | | | | 28,723(5) | | | | | | 28,723(5) | | |
| | | Gross Up Payment | | | | | — | | | | | | — | | |
| | | Total | | | | | 22,568,898 | | | | | | 31,606,416 | | |
Peter Anevski | | | Cash | | | | | 775,000(1) | | | | | | 775,000(1) | | |
| | | Equity Acceleration | | | | | 19,776,314(3) | | | | | | 28,016,479(4) | | |
| | | All Other Payments or Benefits | | | | | 42,107(5) | | | | | | 42,107(5) | | |
| | | Gross Up Payment | | | | | — | | | | | | — | | |
| | | Total | | | | | 20,593,421 | | | | | | 28,833,586 | | |
Mark Livingston | | | Cash | | | | | 467,500(2) | | | | | | 467,500(2) | | |
| | | Equity Acceleration | | | | | 2,186,996(3) | | | | | | 10,191,037(4) | | |
| | | All Other Payments or Benefits | | | | | 31,228(5) | | | | | | 31,228(5) | | |
| | | Total | | | | | 2,685,724 | | | | | | 10,689,765 | | |
Jennifer Bealer(6) | | | Cash | | | | | — | | | | | | — | | |
| | | Equity Acceleration | | | | | — | | | | | | — | | |
| | | All Other Payments or Benefits | | | | | — | | | | | | — | | |
| | | Total | | | | | — | | | | | | — | | |
Plan Category | | | (a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights(1) | | | (b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights | | | (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))(2) | | |||||||||
Equity plans approved by stockholders | | | | | 15,721,139 | | | | | $ | 2.44 | | | | | | 4,824,294 | | |
Equity plans not approved by stockholders | | | | | — | | | | | | — | | | | | | — | | |
Plan Category | | | Number of Shares to be issued upon exercise of outstanding options, warrants and rights (#) | | | Weighted-average exercise price of outstanding options, warrants and rights ($) | | | Number of Shares remaining available for future issuance under equity compensation plans (excluding shares reflected in the first column) (#) | | |||||||||
Equity compensation plans approved by security holders | | | | | 17,254,882(1) | | | | | $ | 24.25 | | | | | | 5,721,311(2) | | |
Equity compensation plan not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 17,254,882 | | | | | $ | 24.25 | | | | | | 5,721,311 | | |
Name | | | Fees Earned or Paid in Cash | | | Option Awards(1)(2) | | | Total | | |||||||||
Fred E. Cohen, M.D., D.Phil. | | | | $ | 9,375 | | | | | $ | 112,328 | | | | | $ | 121,703 | | |
Simeon George, M.D.(3) | | | | | — | | | | | | — | | | | | | — | | |
Kevin Gordon(4) | | | | | 7,500 | | | | | | 274,440 | | | | | | 281,940 | | |
Jeff Park(4) | | | | | 11,250 | | | | | | 319,401 | | | | | | 330,651 | | |
Norman Payson, M.D. | | | | | 8,906 | | | | | | 122,539 | | | | | | 131,445 | | |
Beth Seidenberg, M.D. | | | | | 12,188 | | | | | | 122,539 | | | | | | 134,727 | | |
Cheryl Scott(4) | | | | | 7,500 | | | | | | 274,440 | | | | | | 281,940 | | |
Position | | Annual Retainer | | | Annual Retainer | | ||||||||
Board of Directors | | | $ | 40,000 | | | | | $ | 40,000 | | | ||
Board of Directors Chair | | | | 25,000 | | | ||||||||
Board of Directors Independent Chair or Lead Independent Director | | | $ | 25,000 | | | ||||||||
Audit Committee Chair | | | | 20,000 | | | | | $ | 20,000 | | | ||
Compensation Committee Chair | | | | 10,000 | | | | | $ | 10,000 | | | ||
Nominating and Corporate Governance Committee Chair | | | | 7,500 | | | | | $ | 7,500 | | |
Position | | | Initial Grant | | |||
Board of Directors | | | | | 44,000 | | |
Board of Directors Independent Chair or Lead Independent Director | | | | | 8,800 | | |
Audit Committee Chair | | | | | 6,600 | | |
Compensation Committee Chair | | | | | 4,400 | | |
Nominating and Corporate Governance Committee Chair | | | | | 2,200 | | |
Position | | | Annual Committee Grant (Options) | | | Annual Committee Grant (RSUs) | | ||||||
Board of Directors | | | | $ | 338,587 | | | | | $ | 139,750 | | |
Board of Directors Independent Chair or Lead Independent Director | | | | $ | 54,174 | | | | | $ | 55,900 | | |
Audit Committee Chair | | | | $ | 40,631 | | | | | $ | 27,950 | | |
Compensation Committee Chair | | | | $ | 27,101 | | | | | $ | 27,950 | | |
Nominating and Corporate Governance Committee Chair | | | | $ | 13,544 | | | | | $ | 27,950 | | |
Name(5) | | | Fees Earned or Paid in Cash ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(1) | | | Total ($) | | ||||||||||||
Beth Seidenberg, M.D. | | | | $ | 66,172(2) | | | | | $ | 195,572 | | | | | $ | 430,925 | | | | | $ | 692,669 | | |
Malissia Clinton | | | | $ | 37,452 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 548,640 | | |
Fred Cohen, M.D., D.Phil. | | | | $ | 50,000(3) | | | | | $ | 167,633 | | | | | $ | 401,222 | | | | | $ | 618,855 | | |
Kevin Gordon | | | | $ | 40,000 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 551,187 | | |
Roger Holstein | | | | $ | 37,452 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 548,640 | | |
Jeff Park | | | | $ | 61,079(4) | | | | | $ | 167,633 | | | | | $ | 416,074 | | | | | $ | 644,786 | | |
Norman Payson, M.D. | | | | $ | 47,500 | | | | | $ | 167,633 | | | | | $ | 386,345 | | | | | $ | 601,478 | | |
Cheryl Scott | | | | $ | 40,000 | | | | | $ | 139,694 | | | | | $ | 371,493 | | | | | $ | 551,187 | | |
Name | | | Options Outstanding at Fiscal Year End (Exercisable) | | | Options Outstanding at Fiscal Year End (Unexercisable) | | | Restricted Stock Units Outstanding at Fiscal Year End(1) | | |||||||||
Beth Seidenberg, M.D. | | | | | 66,800 | | | | | | 39,615 | | | | | | 3,094 | | |
Malissia Clinton | | | | | 11,000 | | | | | | 47,658 | | | | | | 2,210 | | |
Fred Cohen, M.D., D. Phil. | | | | | 59,096 | | | | | | 33,981 | | | | | | 2,652 | | |
Kevin Gordon | | | | | 48,833 | | | | | | 34,825 | | | | | | 2,210 | | |
Roger Holstein | | | | | 11,000 | | | | | | 47,658 | | | | | | 2,210 | | |
Jeff Park | | | | | 62,863 | | | | | | 39,180 | | | | | | 2,652 | | |
Norman Payson | | | | | 95,225 | | | | | | 35,043 | | | | | | 2,652 | | |
Cheryl Scott | | | | | 48,834 | | | | | | 34,824 | | | | | | 2,210 | | |
| | | Beneficial Ownership(1) | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
TPG Biotechnology Partners III, L.P.(2) | | | | | 20,661,413 | | | | | | 24.4% | | |
KPCB Holdings, Inc., as nominee(3) | | | | | 19,460,800 | | | | | | 22.9 | | |
S.R. One, Limited(4) | | | | | 10,526,957 | | | | | | 12.4 | | |
David Schlanger(5) | | | | | 4,655,165 | | | | | | 5.2 | | |
Merck Ventures B.V.(6) | | | | | 4,297,414 | | | | | | 5.1 | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Peter Anevski(7) | | | | | 2,407,771 | | | | | | 2.8 | | |
Karin Ajmani(8) | | | | | 1,368,045 | | | | | | 1.6 | | |
Fred E. Cohen, M.D. D. Phil. | | | | | — | | | | | | — | | |
Kevin Gordon | | | | | — | | | | | | — | | |
Jeff Park | | | | | — | | | | | | — | | |
Norman Payson, M.D.(9) | | | | | 3,192,274 | | | | | | 3.8 | | |
Beth Seidenberg, M.D.(10) | | | | | 19,537,723 | | | | | | 23.0 | | |
Cheryl Scott | | | | | — | | | | | | — | | |
All executive officers and directors as a group (10 persons)(11) | | | | | 29,877,320 | | | | | | 33.3 | | |
| | | Beneficial Ownership(1) | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
TPG Biotechnology Partners III, L.P.(2) | | | | | 10,565,351 | | | | | | 11.4% | | |
BlackRock(3) | | | | | 7,923,625 | | | | | | 8.6% | | |
Macquarie Group Limited(4) | | | | | 7,471,794 | | | | | | 8.1% | | |
The Vanguard Group(5) | | | | | 6,475,504 | | | | | | 7.1% | | |
KPCB Holdings, Inc., as nominee(6) | | | | | 6,473,515 | | | | | | 7.1% | | |
Alger Associates, Inc.(7) | | | | | 4,560,319 | | | | | | 5.0% | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Peter Anevski(8) | | | | | 1,992,592 | | | | | | 2.1% | | |
Jennifer Bealer(9) | | | | | 75,788 | | | | | | * | | |
Malissia Clinton(10) | | | | | 16,500 | | | | | | * | | |
Fred E. Cohen, M.D. D. Phil.(11) | | | | | 70,137 | | | | | | * | | |
Kevin Gordon(12) | | | | | 58,416 | | | | | | * | | |
Lisa Greenbaum(13) | | | | | 2,112 | | | | | | * | | |
Roger Holstein(14) | | | | | 16,500 | | | | | | * | | |
Mark Livingston(15) | | | | | 51,875 | | | | | | * | | |
Jeff Park(16) | | | | | 73,446 | | | | | | * | | |
Norman Payson, M.D.(17) | | | | | 759,984 | | | | | | * | | |
David Schlanger(18) | | | | | 3,488,992 | | | | | | 3.7% | | |
Beth Seidenberg, M.D.(19) | | | | | 6,780,721 | | | | | | 7.4% | | |
Cheryl Scott(20) | | | | | 56,417 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(21) | | | | | 13,678,790 | | | | | | 14.0% | | |
| | | | By Order of the Board of Directors | |
| | | | /s/ Jennifer Bealer Jennifer Bealer | |
| | | | Executive Vice President, General Counsel and Secretary | |